Study Highlights Impact of Baseline Visual Acuity on DMO Treatment Outcomes
A recent study, as part of the IRISS post-approval research, has examined the effects of baseline visual acuity (VA) and early treatment on functional outcomes in diabetic macular oedema (DMO). The study focused on the use of fluocinolone acetonide (FAc) implants, a second-line therapy for DMO, particularly when initial treatments with anti-vascular endothelial growth factor agents are insufficient. Conducted across the UK, Germany, and Portugal, the research aimed to assess the safety and long-term effects of the FAc implant. The study categorized patients based on their initial VA into three groups and evaluated their outcomes over time. Results indicated that patients with better initial VA maintained superior visual function for longer periods post-treatment. The study also introduced 'time-in-range' (TIR) as a new metric for assessing long-term treatment success, suggesting it provides a more comprehensive view than traditional VA measures. 
